WO2005095953A3 - Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6) - Google Patents

Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6) Download PDF

Info

Publication number
WO2005095953A3
WO2005095953A3 PCT/EP2005/001738 EP2005001738W WO2005095953A3 WO 2005095953 A3 WO2005095953 A3 WO 2005095953A3 EP 2005001738 W EP2005001738 W EP 2005001738W WO 2005095953 A3 WO2005095953 A3 WO 2005095953A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
ccr6
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/001738
Other languages
French (fr)
Other versions
WO2005095953A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005095953A2 publication Critical patent/WO2005095953A2/en
Publication of WO2005095953A3 publication Critical patent/WO2005095953A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine

Abstract

The invention provides a human CCR6 which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, cancer, metabolic diseases, gastroenterological diseases, hematological diseases, respiratory diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, cancer, metabolic diseases, gastroenterological diseases, hematological diseases, respiratory diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CCR6 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/001738 2004-03-04 2005-02-19 Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6) WO2005095953A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04005081 2004-03-04
EP04005081.7 2004-03-04

Publications (2)

Publication Number Publication Date
WO2005095953A2 WO2005095953A2 (en) 2005-10-13
WO2005095953A3 true WO2005095953A3 (en) 2006-06-22

Family

ID=35064456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001738 WO2005095953A2 (en) 2004-03-04 2005-02-19 Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)

Country Status (1)

Country Link
WO (1) WO2005095953A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2609649C2 (en) 2010-06-28 2017-02-02 Универзитетсклиникум Фрайбург Block of ccl18 signaling through ccr6 as therapeutic method of treating fibrotic diseases and cancer
CN112190708B (en) * 2019-07-08 2023-09-05 上海交通大学医学院附属瑞金医院 Novel use of chemokine receptor CCR6 inhibitors for preventing psoriasis recurrence

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026764A2 (en) * 2000-09-26 2002-04-04 Genaissance Pharmaceuticals, Inc. Haplotypes of the ccr6 gene
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20030153525A1 (en) * 2001-12-19 2003-08-14 Millennium Pharmaceuticals, Inc. Methods and compositions in treating pain and painful disorders using 1465, 1587, 2146, 2207, 32838, 336 and 52908

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026764A2 (en) * 2000-09-26 2002-04-04 Genaissance Pharmaceuticals, Inc. Haplotypes of the ccr6 gene
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20030153525A1 (en) * 2001-12-19 2003-08-14 Millennium Pharmaceuticals, Inc. Methods and compositions in treating pain and painful disorders using 1465, 1587, 2146, 2207, 32838, 336 and 52908

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DELLACASAGRANDE J ET AL: "Liver metastasis of cancer facilitated by chemokine receptor CCR6.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 57, no. 6, June 2003 (2003-06-01), pages 534 - 544, XP008054321, ISSN: 0300-9475 *
DUERIG J ET AL: "Differential expression of chemokine receptors in B cell malignancies", LEUKEMIA (BASINGSTOKE), vol. 15, no. 5, May 2001 (2001-05-01), pages 752 - 756, XP002349495, ISSN: 0887-6924 *
EK SARA ET AL: "Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells", CANCER RESEARCH, vol. 62, no. 15, 1 August 2002 (2002-08-01), pages 4398 - 4405, XP002349494, ISSN: 0008-5472 *
HILBIG CLARKE A ET AL: "SELECTIVE COX-2 INHIBITION SUPPRESSES HUMAN GASTRIC CANCER GROWTH THROUGH ALTERATION OF GENES REGULATING IMMUNE RESPONSE, SIGNALING AND DIFFERENTIATION: A DNA ARRAY ANALYSIS OF 8700 GENES.", DIGESTIVE DISEASE WEEK ABSTRACTS AND ITINERARY PLANNER, vol. 2003, 2003, & DIGESTIVE DISEASE 2003; FL, ORLANDO, USA; MAY 17-22, 2003, pages Abstract No. M1019, XP008054228 *
JOHRER K ET AL: "Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma", CLINICAL CANCER RESEARCH 01 APR 2005 UNITED STATES, vol. 11, no. 7, 1 April 2005 (2005-04-01), pages 2459 - 2465, XP008054225, ISSN: 1078-0432 *
WANG JUN ET AL: "Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype.", CANCER RESEARCH, vol. 64, no. 5, 1 March 2004 (2004-03-01), pages 1861 - 1866, XP002349492, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2005095953A2 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005085466A3 (en) Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
WO2005095631A3 (en) Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)
WO2005075990A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2)
WO2005075983A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)
WO2005100997A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase